The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tripp, R. A.
Right arrow Articles by Brown, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tripp, R. A.
Right arrow Articles by Brown, M. P.
The Journal of Immunology, 2000, 164: 5913-5921.
Copyright © 2000 by The American Association of Immunologists

CD40 Ligand (CD154) Enhances the Th1 and Antibody Responses to Respiratory Syncytial Virus in the BALB/c Mouse

Ralph A. Tripp1,*, Les Jones*, Larry J. Anderson* and Michael P. Brown{dagger}

* Division of Viral and Rickettsial Diseases, National Center of Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333; and {dagger} Cell and Gene Therapy Program, St. Jude Children’s Research Hospital, Memphis, TN 38101


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
CD40 ligand (CD40L) is a cell surface costimulatory molecule expressed mainly by activated T cells. CD40L is critically important for T-B cell and T cell-dendritic cell interactions. CD40L expression promotes Th1 cytokine responses to protein Ags and is responsible for Ig isotype switching in B cells. Respiratory syncytial virus (RSV) is an important pathogen of young children and the elderly, which causes bronchiolitis and pneumonia. Studies of mice infected with RSV suggest that a Th2 cytokine response may be responsible for enhanced pulmonary disease. To investigate the effect CD40L has on RSV immunity, mice were infected simultaneously with RSV and either an empty control adenovirus vector or one expressing CD40L or were coimmunized with plasmid DNA vectors expressing CD40L and RSV F and/or G proteins and subsequently challenged with RSV. The kinetics of the intracellular and secreted cytokine responses, the cytotoxic T lymphocyte precursor frequency, NO levels in lung lavage, rates of virus clearance, and anti-RSV Ab titers were determined. These studies show that coincident expression of CD40L enhances the Th1 (IL-2 and IFN-{gamma}) cytokine responses, increases the expression of TNF-{alpha} and NO, accelerates virus clearance, and increases the anti-F and anti-G Ab responses. These data suggest that CD40L may have the adjuvant properties needed to optimize the safety and efficacy of RSV vaccines.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Worldwide, the most important cause of bronchiolitis and serious lower respiratory tract disease in infants and young children is respiratory syncytial virus (RSV)2 (1, 2, 3). Natural infection with RSV provides limited protection from reinfection and disease, as demonstrated by the recurrence of even severe RSV infections throughout life (4, 5). Moreover, the peak incidence of serious RSV disease is in the young infant who has maternally acquired neutralizing RSV Abs. Thus, the development of RSV vaccines has long been a priority for infants and young children (2, 6, 7, 8, 9), and more recently, vaccines are being developed for older children at risk for serious complications of infection and for the elderly (10, 11, 12). RSV vaccine development has been focused toward live temperature-sensitive, attenuated vaccines and subunit vaccines based on the F and/or G glycoproteins (13, 14). In animal model systems the F glycoprotein is the most effective, and G glycoprotein is the next most effective in inducing neutralizing Abs and protective immunity, but vaccination with the G glycoprotein generally induces only limited protection (15, 16). In clinical studies, no vaccine has yet proven safe and efficacious, mainly because candidate live virus vaccines have been under- or overattenuated or have reverted to the wild-type phenotype (17). However, the recent availability of an RSV infectious clone has expanded the options in developing live virus candidate vaccine strains and renewed hope that a safe and efficacious live virus vaccine can be developed (18, 19). Development of subunit vaccines, in particular, has been hindered by concerns about the enhanced lung disease that occurred in young children who received a formalin-inactivated RSV vaccine and then had natural RSV infection (20). Although the reasons for this vaccine-augmented disease remain uncertain, evidence in the BALB/c mouse model suggests that a heightened Th2 cytokine response may be responsible in part (21, 22, 23). In these studies enhanced lung pathology in formalin-inactivated RSV-vaccinated mice challenged with live RSV was shown to be mediated by Th2-type CD4+ T cells expressing IL-4, IL-5, IL-6, and IL-10. In contrast, mice immunized and challenged with live RSV do not develop extensive lung pathology and respond with a mixed Th1/Th2 immune response (21, 24, 25, 26).

The best indicator of protection from RSV disease is high titers of neutralizing Abs, which is illustrated by the fact that passive administration of high titrated neutralizing RSV Abs can decrease the risk of serious RSV disease (27, 28). Unfortunately, both attenuated live and subunit candidate vaccines induce only modest increases in Abs (29, 30). Consequently, a variety of adjuvants are being evaluated for their ability to enhance the immune response to subunit vaccines (31, 32, 33). In addition, genes for immune-enhancing molecules could be introduced into live virus vaccine candidates using the RSV infectious clone.

One potential immune-enhancing molecule is CD40L. CD40L is critical to productive interactions between T cells and APC (34, 35, 36, 37, 38, 39, 40). A requirement for CD40L in anti-viral immune responses was shown in studies that examined the anti-adenovirus response in CD40L-/- mice. In these studies diminished CD4+ T cell priming and reduced IL-4, IL-10, and IFN-{gamma} cytokine expression occurred in the absence of CD40L (41). The importance of CD40L expression for both the B and T cell immune responses was also shown in CD40L-/- mice challenged with lymphocytic choriomeningitis virus (LCMV) (42, 43). CD40L-/- mice infected with LCMV were capable of generating primary CTL responses, but had defective memory CTL responses. Furthermore, primary anti-LCMV IgG1 Ab responses were severely impaired in the absence of CD40L. The importance of CD40L expression in the development of Th1 cytokine responses was also demonstrated by Ab inhibition studies in which anti-CD40L Ab decreased Th1-mediated autoimmune diabetes in nonobese diabetic mice by reducing IL-12 secretion and slightly increasing IL-4 production (44).

We hypothesize that supplementary CD40L expression during primary RSV infection could promote Th1 over Th2 immune responses, increase the Ab response, and improve the safety and efficacy of RSV vaccines. We examined two different methods that used CD40L as an adjuvant to enhance the immune response to RSV and show that its presence has a broad immune-enhancing effect that might be beneficial for an RSV vaccine.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals

Four- to 6-wk-old, specific-pathogen-free, female BALB/c mice were purchased from Harlan Sprague-Dawley Laboratories (Indianapolis, IN). The mice were housed in microisolator cages and were fed sterilized water and food ad libitum.

Viruses

RSV/A2 (A2) was grown in Vero cells (African green monkey kidney fibroblasts; CCL 81, American Type Culture Collection, Manassas, VA) and maintained in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 2% heat-inactivated (56°C for 30 min) FBS (HyClone, Salt Lake City, UT), 1% L-glutamine, and 1% antibiotic/antimycotic (TCM; all from Life Technologies). Upon visually detectable cytopathic effect, the medium was decanted, replaced with a minimal volume of Dulbecco’s modified PBS (D-PBS), and frozen at -70°C. The flask was thawed, and the loosely adherent cell monolayer was scraped off using a cell scraper (Costar, Cambridge, MA) and collected. The cell lysate and supernatant were centrifuged at 2000 x g for 20 min at 4°C. The resultant supernatants were collected, subdivided into aliquots, and stored at -70°C or in liquid nitrogen vapor. The titer was determined by methylcellulose plaque assay on Vero cells. Virus titer was measured by methylcellulose plaque assay. Virus stock was incubated for 3 h at 37°C on a Vero cell monolayer that was then overlaid with 2% carboxymethylcellulose (Sigma, St. Louis, MO) in TCM and incubated for 5–6 days at 37°C. Finally, the cells were fixed with 4% formalin containing 0.1% crystal violet dye (Sigma), and the end-point titer was determined by macroscopic counting of plaques.

Adenovirus (Ad) constructs

Recombinant replication-defective adenovirus vectors were made using an adenovirus backbone that contained deletions in E1 and E3 regions. The murine CD40L cDNA (45) was cloned into the XbaII and EcoRV sites of the pAVS6 adenoviral transfer plasmid (Genetic Therapy, Gaithersburg, MD) under the control of the Rous sarcoma virus promoter. Control (Ad-VC) and murine CD40L adenovirus vectors (Ad-CD40L) were produced as previously described (46). The empty control adenovirus vector (Ad-VC) was produced under identical conditions, except that it lacked the murine CD40L cDNA insert. Virus titer was measured by plaque assay of 293 cells. Removal of contaminating wild-type virus was achieved by triple-plaque purification, which was confirmed by two observations: 1) absent E1 DNA using a PCR-based method (47), and 2) absent cytopathic effect after supernatants from vector-infected and noncomplementing A549 cells were passaged serially on A549 cells (48).

DNA vectors and vaccination

DNA vaccines were prepared using pcDNA3.1 vector plasmids (Invitrogen, San Diego, CA) constructed with G or F gene cDNA from RSV/A2 (49) or murine CD40L cDNA (46). G gene DNA vaccine (pcDNA-G), F gene DNA vaccine (pcDNA-F), murine CD40L DNA vaccine (pCD40L), and control (pcDNA3.1 only) plasmid constructs were propagated in Escherichia coli SURE2 cells (Stratagene, La Jolla, CA) and purified using an EndoFree Plasmid Giga Kit (Qiagen, Valencia, CA). For immunization, DNA plasmids were precipitated onto 1-µm gold microcarriers (Bio-Rad, Hercules, CA) according to the manufacturer’s instructions. Mice were anesthetized with Avertin (2,2,2-tribromoethanol), their abdomen hair was shaved, and they were immunized in two different locations in the obliquus externus abdominis muscle with 20 µg of DNA vaccine/immunization under helium velocity using the Helios Gene Gun (Bio-Rad). Using a similar immunization procedure, mice were boosted with a total of 40 µg of DNA vaccine every week for 3 wk. To confirm plasmid expression in vivo, serum from eye bleeds was collected weekly and analyzed by ELISA for Abs against RSV-infected and uninfected Vero cells.

Infection, treatment, and sampling

For experiments involving Ad as a vector, mice were anesthetized with Avertin and subsequently infected by i.n. administration of 106 PFU/mouse of A2 immediately followed by i.p. infection with 2 x 107 PFU/mouse with Ad construct Ad-VC or Ad-CD40L or with a PBS control. The Ad vector was given i.p. because of exacerbated pulmonary inflammation that occurred following i.n. administration of both Ad vector and RSV. A dose response of the Ad vectors (2 x 105, 2 x 106, and 2 x 10 7 PFU/mouse) given i.p. suggested that optimal immune enhancement occurred in mice immunized with 2 x 10 7 PFU/mouse. For DNA vaccine experiments, 1 wk following the last of three DNA boosts, mice were anesthetized with Avertin and subsequently challenged by i.n. administration of 106 PFU/mouse of A2. At various time points postinfection (p.i.) mice were anesthetized with Avertin and exsanguinated by severing the right caudal artery, and lymphoid organs and cells were removed. All organs and cells were collected, on ice, in HBSS (Life Technologies). The lung was lavaged three times using HBSS containing 0.1% BSA (Sigma). Four to six mice were used for each experiment , and experiments were repeated on three separate occasions.

Flow cytometry

Bronchoalveolar lavage (BAL) and spleen cells were examined for intracellular cytokine expression directly ex vivo. Single-cell suspensions of lymphocytes were blocked with 10% normal mouse sera (The Jackson Laboratory, Bar Harbor, ME) in D-PBS for 15 min at 4°C. The procedure used for intracellular (IC) cytokine staining was modified for microculture staining from the protocol described by PharMingen (San Diego, CA). Briefly, the cells were washed in PBS (Life Technologies), and the cell surface Ag was stained with the appropriate Ab and subsequently fixed with 4% paraformaldehyde (Ted Pella, Redding, CA) in D-PBS containing 0.1% BSA. The cells were washed in PBS, and the membranes were permeabilized using 0.1% saponin (Sigma). All Abs were PE labeled and purchased from PharMingen. Anti-IL-2 (JES6-5H4), anti-IL-4 (BVD4-1D11), anti-IL-5 (TRFK5), anti-IL-6 (MP5-20F3), anti-IL-12 (C15.6), anti-IFN-{gamma} (XMG1.2), and anti-TNF-{alpha} (MP6-XT22). Ab were diluted in D-PBS containing 0.1% BSA and 0.1% saponin. The cells were stained on ice for 30 min, using appropriate dilutions of the Ab, washed, resuspended in D-PBS containing 0.1% BSA, and analyzed on the FACScan. A lymphocyte gate was used to analyze >=10,000 events. The distribution of cell surface markers was determined in two-color mode on a FACScan with CellQuest software (Becton Dickinson, Mountain View, CA).

FlowMatrix

Secreted cytokines in BAL cell-free exudate were quantitated directly ex vivo using FlowMatrix analysis (Luminex, Austin, TX) and a FACScan (Becton Dickinson) using a modified Ab capture-sandwich assay protocol on defined latex microspheres. In brief, individual prestained red spectrum-colored microsphere bead sets (Luminex) were diluted in PBS/Tween (Sigma), and the capture Abs (anti-IL-2, JES-1A12; anti-IL-4, BVD4-1D11; anti-IL-5, TRFK5; anti-IFN-{gamma}, R4-6A2, all from PharMingen) were covalently coupled to the bead sets using a two-step method described by Luminex. Duplicate dilutions of recombinant murine IL-2, IL-4, IL-5, and IFN-{gamma} (Genzyme, Cambridge, MA) in PBS/Tween were used to generate a standard curve and were assayed against duplicate dilutions of cell-free BAL exudate in PBS. Capture Ab-coated microspheres were incubated with normalized 1-ml standards or unknown 1-ml samples for 30 min at room temperature. Following incubation, ALEXA-streptavidin (Molecular Probes, Eugene, OR)-conjugated biotinylated cytokine detection Abs (IL-2, JES6-5H4; IL-4, BVD6-24G2; IL-5, TRFK4; IFN-{gamma}, XMG1.2; all from PharMingen) were incubated with the samples for 20 min at room temperature. Following incubation, the beads were pelleted by centrifugation, resuspended in PBS/TBN, and analyzed using FACScan and FlowMatrix software.

MHC class I-restricted CTL precursor (CTLp) assays

Class I-restricted target cells used were the mouse mastocytoma line, P815 (American Type Culture Collection, TIB 64). The P815 cell lines was maintained in RPMI 1640 (Life Technologies) containing 10% FBS (HyClone) plus 1% antibiotic/antimycotic (Life Technologies). The target cells were prepared by suspending 106 cells in 1.0 ml of serum-free MEM (Life Technologies) containing 104 PFU/ml RSV cell lysate (or a comparable dilution of uninfected cell control lysate) for 18 h at 37°C followed by addition of 1.0 ml of MEM containing 10% FBS and 200 µCi of 51Cr (Na2CrO4, Amersham, Arlington Heights, IL) and incubating for an additional 2 h at 37°C. The cells were then washed and resuspended to an appropriate concentration in TCM comprised of suspension-MEM (Life Technologies) containing 10% FBS (HyClone), 1% essential amino acids, 2% nonessential amino acids, 2% sodium pyruvate, 2% L-glutamine, 1% antibiotic/antimycotic (all from Life Technologies), and 50 µM 2-ME (Sigma).

Virus-specific CTLp prevalence was determined using a modification of a well-established limiting dilution assay (50). In brief, different dilutions of responder cells in 0.1 ml of TCM were added to wells (24 wells/dilution) of round-bottom, 96-well microtiter plates (Costar) with 0.1 ml of APCs. The APCs were syngeneic splenocytes that had been incubated in a serum-free MEM (Life Technologies) containing 107 PFU/ml RSV for 3 h at 37°C and resuspended at 107 cells/ml in TCM containing 20% EL4.IL-2 supernatant (the lymphoma cell line, EL4.IL-2 (American Type Culture Collection, TIB 181), endogenously secretes IL-2). The responder cells and APCs were incubated at 37°C for 7 days in a humidified atmosphere. The contents of individual wells were then divided in two, placed into replica plates, and incubated for 6 h with 104 51Cr-labeled, RSV-infected or mock-infected target cells. The virus-specific CTLp frequency was estimated using linear regression and 95% confidence intervals about the slope of the regression line plotting the number of cells vs the number of nonresponding cultures. A responding well was defined as one in which the mean 51Cr release from RSV-infected targets plus responding cells was >=3 SD from the mean of 51Cr release from control wells containing uninfected target cells plus responding CTLp. The virus-specific CTLp frequency was estimated according to the Poisson equation at the 37% nonresponding culture point (Fo) along the slope of the linear regression line. The 95% confidence intervals were used to determine significance, which is indicated by p < 0.05%.

Nitrite determination

Nitrite was measured by using a modified Greiss reaction. Briefly, 1 ml cell-free BAL samples were diluted 2-fold with distilled water and deproteinized by zinc sulfate to give a final concentration of 15 g/l . The samples were centrifuged at 1000 x g for 15 min at 10°C, and 0.1-ml aliquots were transferred to microtiter plate wells (Costar). Greiss reagent (0.1 ml; 1 g/l sulfanilamide, 25g/l phosphoric acid, and 0.1 g/l N-1-naphthylethylenediamine) was added to the wells, mixed by gentle pipetting, and allowed to incubate for 15 min at room temperature. The absorbance was read on a microplate reader (Titer-Tek, McLean, VA) at 540 nm. Each sample was assayed in triplicate. Background was determined by treating normalized BAL samples only with 25 g/l phosphoric acid. Sodium nitrite in distilled water was used to generate standard curves.

Determination of anti-RSV Ab titers and Ig isotypes

Mice were anesthetized with Avertin, and 200 µl of peripheral blood was collected from the eye capillary bed. The serum from the peripheral blood was collected and analyzed for RSV Abs by ELISA with RSV-infected or uninfected Vero cell lysate-coated microtiter plates and peroxidase-conjugated anti-mouse Ig (Accurate, Westbury, NY). Ig isotypes were determined using an isotyping kit according to the manufacturer’s instructions (Pierce, Rockford, IL). Specimens were tested at 2-fold dilutions from 1/100 to 1/3200. The ratio of absorbance from RSV-infected cells over the absorbance of uninfected Vero cell lysate was used in analysis of the ELISA results.

Statistical analysis

Each experiment was performed using four to six individual animals. SEMs were calculated for each experiment. The data shown represent the results from one of three separate experiments. The sample variance (s2) between experiments was determined by subtracting the mean from each observation, squaring the differences obtained, and dividing the squared differences by the total number of observations minus {[s2 = {Sigma}i=1(xi - x) (2)/n - 1]}.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
CD40L enhances the expression of intracellular Th1 cytokines

BALB/c mice infected i.n. with RSV were concurrently given saline (sham) treatment i.p. (Fig. 1GoA) or infected with empty adenovirus vector or Ad-VC (Fig. 1GoB) or with Ad vector containing murine CD40L cDNA, and Ad-CD40L (Fig. 1GoC). The kinetics of the IC cytokine response of BAL T cells is shown in Fig. 1Go. BAL T cells from sham-treated mice after RSV challenge expressed peak cytokine levels between days 7 and 14 p.i. (Fig. 1GoA). Expression of Th1 cytokine levels was generally higher than that of Th2 cytokines (Fig. 1GoA). Following RSV infection, BAL T cells from mice infected with Ad-VC (Fig. 1GoB) showed similar kinetics and patterns of cytokine expression as sham-treated mice (Fig. 1GoA). Peak expression levels of Th1 cytokines IL-2 (19%) and IFN-{gamma} (17%), were higher than those of Th2 cytokines, IL-4 (11%), IL-5 (9%), and IL-6 (10%; Fig. 1GoB). In comparison, BAL T cells from mice simultaneously infected with Ad-CD40L and RSV had augmented expression levels of IL-2, IL-6, IL-12, IFN-{gamma}, and TNF-{alpha} and modified cytokine expression kinetics (Fig. 1GoC). Maximal expression levels of IL-2 expression (38%) occurred on day 10 p.i., peak IL-6 expression (18%) occurred on day 10 p.i., peak IL-12 expression (25%) occurred on day 14 p.i., peak IFN-{gamma} expression (36%) occurred on day 10 p.i., and peak TNF-{alpha} expression (34%) occurred on day 14 p.i. (Fig. 1GoC). Expression of IL-4 or IL-5 was not increased in comparison with either sham-treated (Fig. 1GoA) or Ad-VC-infected (Fig. 1GoB) mice, suggesting that coincident expression of CD40L primarily enhanced Th1-type cytokine expression.



View larger version (41K):
[in this window]
[in a new window]
  		FIGURE 1. Kinetics of intracellular cytokine expression by CD3+ T lymphocytes isolated from the BAL after simultaneous i.n. infection with RSV and i.p administration of saline (sham; A), Ad-VC (B), or Ad-CD40L (C). The data for each time point are given as the mean percentage of cells positive for the respective IC cytokine plus SEM of four to six individual mice.

 
Cytokine expression in T cells from the spleen was also analyzed after Ad vector infection and RSV challenge (Fig. 2Go). Although the percentage of CD3+ T cells positive for each cytokine increased post-treatment compared with naive (day 0) values, the percentage of cells expressing each cytokine was lower in spleen than in BAL (Fig. 1Go). The Th1/Th2 cytokine profiles were similar to those observed in T cells from the BAL. Sham-treated mice that were infected with RSV alone maximally expressed Th1 (IL-2, IL-12, and IFN-{gamma}) and Th2 (IL-4, IL-5, and IL-6) cytokines and TNF-{alpha} between days 7 and 10 p.i. (Fig. 2GoA). The cytokine profiles for Ad-VC-infected (Fig. 2GoB) and sham-treated mice were similar, except for a shift in the kinetics of the peak response. Peak cytokine expression for IL-2 (8%), IL-4 (8%), IL-6 (13%), IFN-{gamma} (15%), and TNF-{alpha} (14%) all occurred on day 14 p.i., whereas peak expression of IL-5 (6%) and IL-12 (7%) occurred on day 10 p.i. (Fig. 2GoB). Infection with Ad-CD40L lead to a decrease in the expression of Th2 cytokines and IFN-{gamma} (Fig. 2GoC).



View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 2. Kinetics of intracellular cytokine expression by CD3+ T lymphocytes isolated from the spleen after simultaneous i.n. infection with RSV and i.p administration of saline (sham; A), Ad-VC (B), or Ad-CD40L (C). The data for each time point are given as the mean percentage of cells positive for the respective IC cytokine plus SEM of four to six individual mice.

 
CD40L enhances the secretion of pulmonary Th1 cytokines

The concentrations of Th1 (IL-2 and IFN-{gamma}) and Th2 (IL-4 and IL-5) cytokines in the cell-free BAL fluid of RSV-infected, sham-treated (Fig. 3GoA), Ad-VC-infected (Fig. 3GoB), or Ad-CD40L-infected (Fig. 3GoC) mice were determined. The BAL cytokine responses in sham-treated and Ad-VC-infected mice were moderate compared with those in Ad-CD40L-infected mice. For sham-treated mice, IL-2 and IFN-{gamma} concentrations ranged from 50–100 pg/ml from days 3–14 p.i., and IL-4 and IL-5 ranged from 10–25 pg/ml (Fig. 3GoA). Similar concentrations of secreted cytokines were detected in Ad-VC infected mice (Fig. 3GoB), except that higher levels of IL-2 (200–225 pg/ml) were found between days 7 and 14 p.i. (Fig. 3GoB). The late elevation in IL-2 may reflect an anti-adenovirus T cell response occurring in the lung; Ad given i.p. is expected to infect the lung. In contrast to Ad-VC-associated cytokine levels, much higher levels of IFN-{gamma} were produced in BAL after infection with Ad-CD40L (Fig. 3GoC). In particular, 75–150 pg/ml of IL-2 and 150–300 pg/ml IFN-{gamma} were detected between days 5–7 p.i.; levels peaked on day 10 p.i. (IL-2, 175 pg/ml; IFN-{gamma}, 525 pg/ml;). IL-4 and IL-5 were not detected in the BAL at any time point examined (Fig. 3GoC). These data suggest that infection with Ad-CD40L can enhance the Th1 cytokine response in the lung, especially augmenting the production of IFN-{gamma}.



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 3. Quantification of Th1 (IL-2 and IFN-{gamma}) and Th2 (IL-4 and IL-5) cytokine secretion in the cell-free BAL fluid during the immune response of mice treated simultaneously with RSV i.n. and i.p. injections of saline (sham-treated; A), Ad-VC (B), or Ad-CD40L (C). The data for each time point are given as the mean picograms per milliliter of the cytokine plus SEM of four to six individual mice.

 
Coincident expression of CD40L enhances pulmonary nitrite production associated with enhanced virus clearance

Pulmonary macrophages produce NO to destroy pathogens and invasive organisms. The NO reaction produces nitrite, molecular oxygen, and water; thus, nitrite levels correlate well with NO production (22). Nitrite concentrations were analyzed in cell-free BAL from sham-treated, Ad-VC-infected, and Ad-CD40L-infected mice that were challenged simultaneously with RSV (Fig. 4Go). BAL nitrite levels peaked between days 5 and 7 p.i. in sham-treated (90 µM), Ad-VC-infected (125 µM), and Ad-CD40L-infected (160 µM) mice. By day 10 p.i., BAL nitrite levels declined in sham-treated mice (25 µM), but remained high in Ad-VC-infected and Ad-CD40L-infected mice. By day 14 p.i., nitrite levels had dropped to the 20–35 µM range in all groups (Fig. 4Go).



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 4. Nitrite levels produced in the cell-free BAL of mice treated simultaneously with RSV and i.p. injections of saline (sham-treated), Ad-VC, or Ad-CD40L. The data for each time point are given as micromolar concentrations of nitrite plus SEM of four to six individual mice.

 
Enhanced virus clearance was observed in mice infected with Ad-CD40L compared with sham-treated or Ad-VC-infected mice (Table IGo). Ad-CD40L-infected mice challenged with RSV cleared virus by day 7 p.i., whereas sham-treated and Ad-VC-infected mice cleared virus between days 10–14 p.i. (Table IGo). Moreover, Ad-CD40L-treated mice exhibited reduced RSV titers on day 6 p.i. compared with sham-treated or Ad-VC-infected mice. No significant differences in virus clearance were observed at any time point examined between Ad-VC-infected and PBS-treated mice. The enhanced virus clearance correlated temporally with CD40L expression, increased pulmonary NO production, and enhanced IC Th1 cytokines and pulmonary Th1 cytokine secretion.


View this table:
[in this window]
[in a new window]
  		Table I. Titer of RSV in lungs of mice

 
RSV-specific MHC class I-restricted CTLp frequencies persist in CD40L-treated mice

To address the effect of coincident CD40L expression on the pulmonary RSV-specific CTLp frequency, MHC class I-restricted CTLp frequencies were measured in the BAL from sham-treated, Ad-VC-infected, and Ad-CD40L-infected mice at various times following RSV challenge (Fig. 5Go). The average values from all experiments (n = 9) are summarized and show that infection with Ad-CD40L helps to sustain a higher frequency (average, 1/6,000) of RSV-specific CTLp at a later time point (day 21 p.i.) in the lung than either sham treatment (average, 1/8,200) or Ad-VC treatment (average, 1/13,500) mice. Peak CTLp frequencies for all treatments following RSV challenge occurred between days 10 and 14 p.i. (range, 1:3,300–1:4,100). After day 14 p.i., there was a greater decrease in RSV-specific CTLp in the lungs of sham-treated and Ad-VC-infected mice, whereas there was less of a decline in CTLp frequency for Ad-CD40L-infected mice, especially compared with the Ad-VC control. The overall decline in CTLp frequency on day 14 p.i. probably reflects cell trafficking from the lung due to virus elimination and a decreased inflammatory response. The heightened CTLp frequencies for Ad-CD40L-infected mice compared with PBS-treated or Ad-VC-infected mice on day 14 postinfection may be the effect of increased cytokine expression, particularly IFN-{gamma} (Fig. 3Go), associated with CD40L expression.



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 5. CTLp frequencies during the immune response of mice simultaneously challenged with RSV i.n. and given i.p. injections of saline (sham-treated), Ad-VC, or AD-CD40L. The frequencies of class I-restricted CTLp and the ranges are shown for nine experiments. Significant differences are given by 95% confidence limits.

 
CD40L expression enhances anti-RSV Ab titers

To determine the effect of CD40L expression on the anti-RSV Ab response, mice were sham treated with PBS, infected with Ad-VC, or infected with Ad-CD40L and simultaneously challenged with RSV; the sera were collected and analyzed on days 14 and 21 p.i.. As the same rank order of Ig isotype concentrations (IgG2a > IgG2b > IgG1 > IgM > IgG3 > IgG1) applied to all groups examined, no distinct Th1- or Th2-type humoral pattern emerged in relation to any of the infections. However, mice infected with Ad-CD40L did develop a higher titer of anti-RSV Ab, i.e., a 2-fold higher increase in titer on day 21 p.i. (1/3200) compared with sham-treated mice (1/1600) or mice infected with Ad-VC (1/1600).

To determine whether CD40L could augment the Ab response to RSV, mice were intradermally immunized each week for 3 consecutive weeks with the empty plasmid DNA vector or with the vectors that encoded F or G subunits or F-CD40L, G-CD40L, or F-G-CD40L and then challenged 1 wk later with RSV (Fig. 6Go). Peak Ab titers after DNA immunizations but before RSV challenge ranged between 1/100 and 1/200. After RSV challenge, anti-RSV Ab titers exceeded 1/3200 for all mice except those immunized with the G subunit vector alone (Fig. 6Go). The anti-RSV Ab responses were enhanced by the addition of the CD40L vector, as indicated by higher absorbance ratios at the 1/3200 dilution (Fig. 6Go). A striking 7-fold increase in the Ab response (i.e., absorbance ratio) to the G subunit vector was induced by the addition of CD40L.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 6. RSV-specific Ab titers in sera from DNA-immunized mice challenged 1 wk later with RSV. Mice were immunized intradermally each week for 3 wk using plasmid-coated gold beads administered by gene gun. Mice were immunized singly or in combination with plasmid DNA vectors that encoded F or G subunits or CD40L and subsequently challenged i.n. with 106 PFU of RSV/A2. Sera were collected 2 wk post-RSV challenge and examined by ELISA for anti-RSV Ab titers. The data are expressed as ratios of the absorbance values for RSV-infected Vero cell lysates divided by uninfected Vero cell lysates. The results shown are the mean absorbance ratios for serum at a serum dilution of 1/3200 from five or six mice ± SE.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Our findings support our hypothesis that expression of CD40L during RSV infection or immunization would enhance the overall immune response and promote a Th1-type over a Th2-type response. Previous studies suggested that CD40L might enhance both humoral and cellular immune responses (35, 36, 51, 52, 53, 54). CD40L expression has been shown to enhance T cell and APC activation and signaling, the importance of which has been revealed by studies of CD40L-/- mice (42, 55, 56, 57, 58, 59, 60, 61, 62) and CD40L-/- humans (63). Coincident expression of CD40L has been shown to promote T cell-mediated immunity (37, 41, 64, 65, 66). Constitutive retroviral expression of CD40L restored Ag-specific cytolytic and humoral immune responses in CD40L-/- mice infected intranasally with the HKx31 strain of influenza (66). Immunization of BALB/c mice with DNA plasmids expressing ß-galactosidase and CD40L increased the Th1-type immune response to ß-galactosidase (51). Infection of mice with recombinant vaccinia virus that expressed CD40L markedly enhanced viral clearance by both an IFN-{gamma}-dependent mechanism and a novel CD40L-dependent mechanism (64). Administering anti-CD40 mAb to mice together with pneumococcal polysaccharide generated strong, isotype-switched Ab responses (67).

Our studies also revealed that CD40L expression coincident with RSV infection or coexpressed during DNA vaccination had broad immune-enhancing effects. CD40L enhanced the levels of IL-2 and IFN-{gamma} (Figs. 1Go and 3Go), increased pulmonary NO synthesis (Fig. 4Go), increased the frequency of RSV-specific CTL precursors in the lung (Fig. 5Go), increased the anti-RSV Ab response (Fig. 6Go), and decreased the RSV clearance time (Table IGo). The increase in pulmonary NO production associated with CD40L treatment may have contributed to the more rapid clearance of RSV. NO is believed to inhibit an early stage of viral replication and spread (68), possibly by activating APC (69) and the associated increased production by APC of TNF-{alpha} and IFN-{gamma} and activation of bystander T cells (70). CD40L expressed by Th cells is a major contributor to T cell-dependent NO production by macrophage, and reduced macrophage production in CD40L-deficient mice enhanced susceptibility to Leishmania infection (61, 62). The increased expression of TNF-{alpha} and IFN-{gamma} and the enhanced Ab response could also contribute to the accelerated clearance of RSV from the lungs (Table IGo).

Although we did not observe an overall increase in RSV-specific CTLp frequency with CD40L expression, the higher CTLp frequency observed at 21 day p.i. compared with that with control treatments raises the possibility that CD40L may enhance the duration of the RSV-specific CTL response (Fig. 5Go). In studies of CD40L-/- mice infected with LCMV and Pichinde virus, the primary CTL response was normal, but the memory response was defective (42).

Finally, coexpression of CD40L with F and G proteins enhanced the RSV Ab response to later RSV challenge (Fig. 6Go). This priming effect was most pronounced for the anti-G Ab response. Because a high titer of neutralizing RSV Abs may be needed for effective protection as has been shown in passive Ab studies (28, 71), we presume that the same may also apply for RSV vaccination. If this is the case, then expression of CD40L with a RSV vaccine may enhance the RSV Ab response and thus the protective immune response.

In summary, our results indicate that supplementary expression of CD40L broadly enhances the RSV immune response and directs this response toward a Th1 phenotype. The results suggest that CD40L can enhance RSV immunity and might be a useful adjuvant for an RSV vaccine.


   Acknowledgments
 
We thank Dr. Janet Houghton for supplying the Ad vector control plasmid used in this study, Dr. Mike Grossmann and Jingfeng Zhao for technical assistance, and Dr. Linda Harris for helpful comments and suggestions.


   Footnotes
 
1 Address correspondence and reprint requests to Dr. Ralph A. Tripp, Centers for Disease Control and Prevention, 1600 Clifton Road, MS G09, Atlanta, GA 30333. Back

2 Abbreviations used in this paper: RSV, respiratory syncytial virus; CD40L, CD40 ligand; LCMV, lymphocytic choriomeningitis virus; D-PBS, Dulbecco’s modified PBS; Ad, adenovirus; i.n., intranasally; BAL, bronchoalveolar lavage; IC, intracellular; p.i., postinfection; CTLp, CTL precursor. Back

Received for publication November 23, 1999. Accepted for publication March 21, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Collins, P., K. McIntosh, R. Chanock. 1996. Respiratory syncytial virus. , , , ed. Fields Virology 3rd Ed.1313. Lippincott-Raven, Philadelphia.
  2. Jr Crowe, J. E.. 1995. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV): a meeting report of the WHO Program for Vaccine Development. Vaccine 13:415.[Medline]
  3. Welliver, R. C., M. R. Gallagher, P. L. Ogra. 1981. Clinical and laboratory diagnosis of respiratory syncytial virus infection. Crit. Rev. Clin. Lab. Sci. 13:213.[Medline]
  4. Hall, C., E. Walsh, C. Long, K. Schnabel. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163:693.[Medline]
  5. Henderson, F., A. Collier, W. Clyde, F. Denny. 1979. Respiratory syncytial virus infections, reinfections and immunity: a prospective. longitudinal study in young children. N. Engl. J. Med. 300:530.[Abstract]
  6. 1985. New Vaccine Development: Establishing Priorities, Vol. 1: Diseases of Importance in the United States. National Academy Press, Washington, D.C.
  7. 1986. New Vaccine Development: Establishing Priorities, Vol 2: Diseases of Importance in Developing Countries. National Academy Press, Washington, D.C.
  8. Doherty, P. C.. 1994. Vaccines and cytokine-mediated pathology in RSV infection. Trends Microbiol. 2:148.[Medline]
  9. Murphy, B. R., G. A. Prince, P. L. Collins, K. Van Wyke Coelingh, R. A. Olmsted, M. K. Spriggs, R. H. Parrott, H. W. Kim, C. D. Brandt, R. M. Chanock. 1988. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 11:1.[Medline]
  10. Piedra, P. A., S. Grace, A. Jewell, S. Spinelli, D. Bunting, D. A. Hogerman, F. Malinoski, P. W. Hiatt. 1996. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J. 15:23.[Medline]
  11. Han, L. L., J. P. Alexander, L. J. Anderson. 1999. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. 179:25.[Medline]
  12. Falsey, A. R., E. Walsh. 1997. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 15:1130.[Medline]
  13. Groothuis, J. R., S. J. King, D. A. Hogerman, P. R. Paradiso, E. A. Simoes. 1998. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect Dis. 177:467.[Medline]
  14. Siegrist, C. A., H. Plotnicky-Gilquin, M. Cordova, M. Berney, J. Y. Bonnefoy, T. N. Nguyen, P. H. Lambert, U. F. Power. 1999. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J. Infect. Dis. 179:1326.[Medline]
  15. Stott, E., G. Taylor, L. Ball, K. Anderson, K. K. Young, A. M. King, G. Wertz. 1987. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61:3855.[Abstract/Free Full Text]
  16. Connors, M., P. L. Collins, C. Y. Firestone, B. R. Murphy. 1991. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65:1634.[Abstract/Free Full Text]
  17. Karron, R. A., P. F. Wright, Jr J. E. Crowe, M. L. Clements-Mann, J. Thompson, M. Makhene, R. Casey, B. R. Murphy. 1997. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis. 176:1428.[Medline]
  18. Teng, M. N., P. L. Collins. 1999. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J. Virol. 73:466.[Abstract/Free Full Text]
  19. Whitehead, S. S., C. Y. Firestone, R. A. Karron, Jr J. E. Crowe, W. R. Elkins, P. L. Collins, B. R. Murphy. 1999. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J. Virol. 73:871.[Abstract/Free Full Text]
  20. Chin, J., R. L. Magoffin, L. A. Shearer, J. H. Schieble, E. H. Lennette. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449.[Abstract/Free Full Text]
  21. Anderson, L. J., C. Tsou, C. Potter, H. L. Keyserling, T. F. Smith, G. Ananaba, C. R. Bangham. 1994. Cytokine response to respiratory syncytial virus stimulation of human peripheral blood mononuclear cells. J. Infect. Dis. 170:1201.[Medline]
  22. Connors, M., N. A. Giese, A. B. Kulkarni, C. Y. Firestone, III H. C. Morse, B. R. Murphy. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:5321.[Abstract/Free Full Text]
  23. Waris, M. E., C. Tsou, D. D. Erdman, S. R. Zaki, L. J. Anderson. 1996. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:2852.[Abstract]
  24. Graham, B. S., G. S. Henderson, Y. W. Tang, X. Lu, K. M. Neuzil, D. G. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032.[Abstract]
  25. Hussell, T., L. C. Spender, A. Georgiou, A. O’ Garra, P. J. Openshaw. 1996. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. J. Gen. Virol. 77:2447.[Abstract/Free Full Text]
  26. Srikiatkhachorn, A., T. J. Braciale. 1997. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 71:678.[Abstract]
  27. Groothuis, J. R., M. J. Levin, W. Rodriguez, C. B. Hall, C. E. Long, H. W. Kim, B. A. Lauer, V. G. Hemming. 1991. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics: The RSVIG Study Group. Antimicrob. Agents Chemother. 35:1469.[Abstract/Free Full Text]
  28. Hemming, V. G., G. A. Prince, J. R. Groothuis, G. R. Siber. 1995. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8:22.[Abstract]
  29. Dudas, R. A., R. A. Karron. 1998. Respiratory syncytial virus vaccines. Clin. Microbiol. Rev. 11:430.[Abstract/Free Full Text]
  30. Murphy, B. R., S. L. Hall, A. B. Kulkarni, Jr J. E. Crowe, P. L. Collins, M. Connors, R. A. Karron, R. M. Chanock. 1994. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:13.[Medline]
  31. Neuzil, K., J. Johnson, Y.-W. Tang, J.-P. Prieels, M. Slaoui, N. Gar, B. Graham. 1997. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 15:525.[Medline]
  32. Ciupitu, A. M., M. Petersson, C. L. O’Donnell, K. Williams, S. Jindal, R. Kiessling, R. M. Welsh. 1998. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187:685.[Abstract/Free Full Text]
  33. Hancock, G. E., D. J. Speelman, P. J. Frenchick, M. M. Mineo-Kuhn, R. B. Baggs, D. J. Hahn. 1995. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in BALB/c mice that are similar to those generated by experimental infection. Vaccine 13:391.[Medline]
  34. Armitage, R. J., C. R. Maliszewski, M. R. Alderson, K. H. Grabstein, M. K. Spriggs, W. C. Fanslow. 1993. CD40L: a multi-functional ligand. Semin. Immunol. 5:401.[Medline]
  35. Grewal, I. S., R. A. Flavell. 1997. The CD40 ligand: at the center of the immune universe?. Immunol. Res. 16:59.[Medline]
  36. Laman, J. D., E. Claassen, R. J. Noelle. 1996. Functions of CD40 and its ligand, gp39 (CD40L). Crit. Rev. Immunol. 16:59.[Medline]
  37. Ramshaw, I. A., A. J. Ramsay, G. Karupiah, M. S. Rolph, S. Mahalingam, J. C. Ruby. 1997. Cytokines and immunity to viral infections. Immunol. Rev. 159:119.[Medline]
  38. van Kooten, C., J. Banchereau. 1997. Functional role of CD40 and its ligand. Int. Arch. Allergy Immunol. 113:393.[Medline]
  39. van Kooten, C., J. Banchereau. 1997. Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9:330.[Medline]
  40. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. Miller, W. R. Heath. 1998. Help for a cytotoxic-T-cell response is mediated by CD40 signaling. Nature 393:478.[Medline]
  41. Yang, Y., Q. Su, I. S. Grewal, R. Schilz, R. A. Flavell, J. M. Wilson. 1996. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70:6370.[Abstract]
  42. Borrow, P., A. Tishon, S. Lee, J. Xu, I. S. Grewal, M. B. Oldstone, R. A. Flavell. 1996. CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J. Exp. Med. 183:2129.[Abstract/Free Full Text]
  43. Oxenius, A., K. A. Campbell, C. R. Maliszewski, T. Kishimoto, H. Kikutani, H. Hengartner, R. M. Zinkernagel, M. F. Bachmann. 1996. CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J. Exp. Med. 183:2209.[Abstract/Free Full Text]
  44. Balasa, B., T. Krahl, G. Patstone, J. Lee, R. Tisch, H. O. McDevitt, N. Sarvetnick. 1997. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. 159:4620.[Abstract]
  45. Dilloo, D., M. Brown, M. Roskrow, W. Y. Zhong, W. Holden, M. Holladay, M. K. Brenner. 1997. CD40 ligand induces an antileukemia immune response in vivo. Blood 90:1927.[Abstract/Free Full Text]
  46. Leimig, T., M. Brenner, J. Ramsey, E. Vanin, M. Blaese, D. Dilloo. 1996. High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors. Hum. Gene Ther. 7:1233.[Medline]
  47. Zhang, W. W., P. E. Koch, J. A. Roth. 1995. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. BioTechniques 18:444.[Medline]
  48. Gorziglia, M. I., M. J. Kadan, S. Yei, J. Lim, G. M. Lee, R. Luthra, B. C. Trapnell. 1996. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70:4173.[Abstract]
  49. Sullender, W.. 1995. Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus. Virology 209:70.[Medline]
  50. Tripp, R., L. Anderson. 1998. Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine. J. Virol. 72:8971.[Abstract/Free Full Text]
  51. Gurunathan, S., K. R. Irvine, C. Y. Wu, J. I. Cohen, E. Thomas, C. Prussin, N. P. Restifo, R. A. Seder. 1998. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J. Immunol. 161:4563.[Abstract/Free Full Text]
  52. Durie, F. H., T. M. Foy, S. R. Masters, J. D. Laman, R. J. Noelle. 1994. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today 15:406.[Medline]
  53. Klaus, S. J., I. Berberich, G. Shu, E. A. Clark. 1994. CD40 and its ligand in the regulation of humoral immunity. Semin. Immunol. 6:279.[Medline]
  54. Noelle, R. J.. 1998. CD40 and its ligand in cell-mediated immunity. Agents Actions 49:(Suppl.):17.
  55. Castigli, E., F. W. Alt, L. Davidson, A. Bottaro, E. Mizoguchi, A. K. Bhan, R. S. Geha. 1994. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc. Natl. Acad. Sci. USA 91:12135.[Abstract/Free Full Text]
  56. Cosyns, M., S. Tsirkin, M. Jones, R. Flavell, H. Kikutani, A. R. Hayward. 1998. Requirement of CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice. Infect Immun. 66:603.[Abstract/Free Full Text]
  57. Grewal, I. S., J. Xu, R. A. Flavell. 1995. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378:617.[Medline]
  58. Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, H. Kikutani. 1994. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1:167.[Medline]
  59. Kennedy, M. K., K. S. Picha, W. C. Fanslow, K. H. Grabstein, M. R. Alderson, K. N. Clifford, W. A. Chin, K. M. Mohler. 1996. CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur. J. Immunol. 26:370.[Medline]
  60. Lei, X. F., Y. Ohkawara, M. R. Stampfli, C. Mastruzzo, R. A. Marr, D. Snider, Z. Xing, M. Jordana. 1998. Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice. J. Clin. Invest. 101:1342.[Medline]
  61. Soong, L., J. C. Xu, I. S. Grewal, P. Kima, J. Sun, Jr B. J. Longley, N. H. Ruddle, D. McMahon-Pratt, R. A. Flavell. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4:263.[Medline]
  62. Stout, R. D., J. Suttles, J. Xu, I. S. Grewal, R. A. Flavell. 1996. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156:8.[Abstract]
  63. Allen, R. C., R. J. Armitage, M. E. Conley, H. Rosenblatt, N. A. Jenkins, N. G. Copeland, M. A. Bedell, S. Edelhoff, C. M. Disteche, D. K. Simoneaux, et al 1993. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259:990.[Abstract]
  64. Ruby, J., H. Bluethmann, M. Aguet, I. A. Ramshaw. 1995. CD40 ligand has potent antiviral activity. Nat. Med. 1:437.[Medline]
  65. Couderc, B., L. Zitvogel, V. Douin-Echinard, L. Djennane, H. Tahara, G. Favre, M. T. Lotze, P. D. Robbins. 1998. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 5:163.[Medline]
  66. Brown, M. P., D. J. Topham, M. Y. Sangster, J. Zhao, K. J. Flynn, S. L. Surman, D. L. Woodland, P. C. Doherty, A. G. Farr, P. K. Pattengale, et al 1998. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat. Med. 4:1253.[Medline]
  67. Dullforce, P., D. C. Sutton, A. W. Heath. 1998. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat. Med. 4:88.[Medline]
  68. Pope, M., P. A. Marsden, E. Cole, S. Sloan, L. S. Fung, Q. Ning, J. W. Ding, J. L. Leibowitz, M. J. Phillips, G. A. Levy. 1998. Resistance to murine hepatitis virus strain 3 is dependent on production of nitric oxide. J. Virol. 72:7084.[Abstract/Free Full Text]
  69. MacMicking, J., Q. W. Xie, C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323.[Medline]
  70. DeKruyff, R. H., R. S. Gieni, D. T. Umetsu. 1997. Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J. Immunol. 158:359.[Abstract]
  71. Fixler, D. E.. 1996. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatr. Cardiol. 17:163.[Medline]



This article has been cited by other articles:


Home page
 J. Virol.Home page
I. Skountzou, F.-S. Quan, S. Gangadhara, L. Ye, A. Vzorov, P. Selvaraj, J. Jacob, R. W. Compans, and S.-M. Kang
Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- Macrophage Colony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles
J. Virol., February 1, 2007; 81(3): 1083 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
S. L. Gares, K. P. Fischer, S. E. Congly, S. Lacoste, W. R. Addison, D. L. Tyrrell, and K. S. Gutfreund
Immunotargeting with CD154 (CD40 Ligand) Enhances DNA Vaccine Responses in Ducks.
Clin. Vaccine Immunol., August 1, 2006; 13(8): 958 - 965.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Manoj, P. J. Griebel, L. A. Babiuk, and S. van Drunen Littel-van den Hurk
Targeting with Bovine CD154 Enhances Humoral Immune Responses Induced by a DNA Vaccine in Sheep
J. Immunol., January 15, 2003; 170(2): 989 - 996.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
L. P. Jones, H.-Q. Zheng, R. A. Karron, T. C. T. Peret, C. Tsou, and L. J. Anderson
Multiplex Assay for Detection of Strain-Specific Antibodies against the Two Variable Regions of the G Protein of Respiratory Syncytial Virus
Clin. Vaccine Immunol., May 1, 2002; 9(3): 633 - 638.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Nierkens, P. van Helden, M. Bol, R. Bleumink, P. van Kooten, S. Ramdien-Murli, L. Boon, and R. Pieters
Selective Requirement for CD40-CD154 in Drug-Induced Type 1 Versus Type 2 Responses to Trinitrophenyl-Ovalbumin
J. Immunol., April 15, 2002; 168(8): 3747 - 3754.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
J.-Y. Wu, R. K. Taylor, and W. F. Wade
Anti-Class II Monoclonal Antibody-Targeted Vibrio cholerae TcpA Pilin: Modulation of Serologic Response, Epitope Specificity, and Isotype
Infect. Immun., December 1, 2001; 69(12): 7679 - 7686.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
I. Davis and S. Matalon
Reactive Species in Viral Pneumonitis: Lessons From Animal Models
Physiology, August 1, 2001; 16(4): 185 - 190.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map